Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study

Atherosclerosis
C KoopalFrank L J Visseren

Abstract

Familial dysbetalipoproteinemia (FD), also known as type III hyperlipoproteinemia, is a genetic dyslipidemia characterized by elevated very low density lipoprotein (VLDL) and chylomicron remnant particles that confers increased risk of cardiovascular disease (CVD). The objective of this study was to evaluate the prevalence of vascular risk factors, CVD, lipid values, treatment and lipid targets in patients with FD across Europe. This cross-sectional study was performed in 305 patients with FD from seven academic hospitals in four European countries. Information was collected from clinical records. Patients mean (±standard deviation) age was 60.9±14.4 years, 201 (66%) were male, 69 (23%) had diabetes mellitus (DM) and 87 (29%) had a prior history of CVD. Mean body mass index was 28.5±5.0 kg/m2. Lipid-lowering medication was used by 227 (74%) patients (27% usual dose (theoretical low-density lipoprotein cholesterol (LDL-C) reduction≤40%) and 46% intensive dose (theoretical LDL-C reduction>40%)). Non high-density lipoprotein cholesterol (non-HDL-C) levels below treatment target (<3.3 mmol/L) were present in 123 (40%) patients and 163 patients (53%) had LDL-C levels below target (<2.5 mmol/L). No significant determinants were found...Continue Reading

References

Dec 20, 1996·Atherosclerosis·F CiveiraJ M Ordovás
Jul 1, 1999·American Heart Journal·J R Guyton
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Sep 2, 1955·Science·J NEYMAN
Sep 11, 2004·Journal of the American College of Cardiology·Scott M GrundyUNKNOWN Coordinating Committee of the National Cholesterol Education Program
Apr 6, 2005·Journal of the American College of Cardiology·Paul N HopkinsEliot A Brinton
Sep 19, 2006·Journal of Clinical Epidemiology·A Rogier T DondersKarel G M Moons
Sep 20, 2007·JAMA : the Journal of the American Medical Association·Anna M BennetJohn Danesh
Nov 27, 2008·European Journal of Human Genetics : EJHG·Juergen R Schaefer
Nov 27, 2008·European Journal of Human Genetics : EJHG·Peter HennemanAugustinus H M Smelt
Jan 24, 2009·Journal of the American College of Cardiology·Jennifer G RobinsonTerry A Jacobson
Feb 24, 2009·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Kjetil RetterstølPer Ole Iversen
Jun 30, 2011·European Heart Journal·UNKNOWN European Association for Cardiovascular Prevention & RehabilitationUNKNOWN ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
Aug 21, 2012·The Medical Journal of Australia·David W JohnsonUNKNOWN Australasian Proteinuria Consensus Working Group
Dec 26, 2012·Journal of the American College of Cardiology·Anette VarboBørge G Nordestgaard
Aug 21, 2013·Journal of the American College of Cardiology·Anton P van de WoestijneUNKNOWN SMART Study Group
Sep 26, 2013·Nature Reviews. Cardiology·Gerald F WattsDick C Chan
Jan 11, 2014·Critical Reviews in Clinical Laboratory Sciences·A D MaraisD J Blom

❮ Previous
Next ❯

Citations

Dec 10, 2015·Archives of Physiology and Biochemistry·Sahla BelHadjAbdel Fattah El Feki
Jul 4, 2015·Diagnostic Pathology·Negin AbedinzadehAram Mokarizadeh
Aug 3, 2016·Progress in Cardiovascular Diseases·Conrad B Blum
Jan 21, 2017·Current Opinion in Endocrinology, Diabetes, and Obesity·Dan Streja
Jan 19, 2017·Current Opinion in Endocrinology, Diabetes, and Obesity·Charlotte KoopalFrank L J Visseren
Apr 8, 2020·Critical Reviews in Clinical Laboratory Sciences·Christopher S BootRobert D G Neely
Aug 28, 2020·Frontiers in Endocrinology·Debapriya Basu, Karin E Bornfeldt
Apr 26, 2020·Current Opinion in Lipidology·Carlos A Aguilar Salinas, M John Chapman
Jan 22, 2020·Journal of Clinical Lipidology·Martine PaquetteAlexis Baass
May 20, 2021·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Teresa PadroLina Badimon
May 20, 2021·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Ana CenarroFernando Civeira
Sep 8, 2021·The Journal of Clinical Investigation·Masami Shimizu-AlbergineKarin E Bornfeldt

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

American Health & Drug Benefits
Marsha J Daniel
Current Diabetes Reports
Hemanth NeeliDaniel J Rader
Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis
Ángel Julián Brea Hernando
© 2021 Meta ULC. All rights reserved